Gilead Sciences (GILD) April weeky calls active on open
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Gilead Sciences (GILD) Remdesivir China Results 'Very Sobering' - Baird
April 23, 2020 1:34 PM EDTBaird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) related to news that a China trial of severe patients showed remdesivir didn't improve patients' condition.
Skorney commented, "This afternoon, an abstract leaked indicating that Gilead's remdesivir failed to provide a benefit... More
